Influenza B Ag Rapid Test Device

Influenza B is one of the major seasonal flu viruses. It can cause fever, cough, sore throat, headache, body ache, chills, tiredness, and respiratory discomfort. Because symptoms of Influenza B may overlap with Influenza A, COVID-19, RSV, and common cold infections, rapid testing helps healthcare professionals make faster screening decisions.

• The Influenza B Ag Rapid Test Device helps support early flu screening during seasonal outbreaks.
• Influenza B can cause significant illness, especially in children, older adults, pregnant women, and people with weakened immunity or chronic health conditions.
• Rapid testing may support early clinical decision-making, infection-control planning, patient isolation guidance, and respiratory outbreak monitoring.
• Fast influenza screening may also help reduce unnecessary antibiotic use and support timely treatment decisions.

The Influenza B Ag Rapid Test Device by LARKSOIS Pharma may be used in professional diagnostic and respiratory infection screening environments.

Applications

• Hospitals and clinics
• Fever clinics
• Diagnostic laboratories
• Emergency departments
• Respiratory infection programs
• Professional point-of-care testing
• Seasonal flu outbreak screening
• Public health screening support
• International diagnostic distribution

• The Influenza B Ag Rapid Test Device works on lateral flow immunochromatographic assay technology.
• After collecting the nasal or nasopharyngeal swab specimen, the swab is mixed with extraction buffer.
• The prepared sample is then added to the test device.
• If Influenza B antigen is present at or above the test detection level, it reacts with specific antibodies on the test membrane and forms a visible test line.
• A control line confirms proper sample migration and valid test performance.

The Influenza B Ag Rapid Test Device uses rapid lateral flow immunochromatographic technology for qualitative detection of Influenza B antigen in nasal or nasopharyngeal swab specimens.

Benefits

• Detects Influenza B antigen
• Uses nasal or nasopharyngeal swab samples
• Rapid visual result
• Simple test procedure
• No complex instrument required
• Suitable for professional point-of-care testing
• Useful during seasonal flu outbreaks
• Supports international diagnostic supply needs

The Influenza B Ag Rapid Test Device is suitable for nasopharyngeal swabs and nasal swabs. Proper specimen collection is important because poor sample quality can lead to false-negative results.

Guidance

• Use approved nasal or nasopharyngeal swab specimens only
• Collect specimens according to the product insert
• Use clean and suitable swab collection materials
• Avoid contaminated or improperly collected samples
• Mix the swab specimen with extraction buffer correctly
• Apply the prepared sample properly to the test device
• Read results only within the recommended time window
• Handle respiratory specimens according to laboratory safety procedures

Note

Specimen collection, extraction, testing, timing, and storage should always follow the official LARKSOIS Pharma kit insert.

The Influenza B Ag Rapid Test Device by LARKSOIS Pharma is designed for qualitative detection of Influenza B antigen in nasal or nasopharyngeal swab specimens. The listed cut-off is 100 TCID/ml, and results should be interpreted with symptoms, patient history, exposure risk, and local flu activity.

• A positive result means Influenza B antigen has been detected.
• Rapid detection may support timely clinical decisions and infection-control measures.
• A negative result does not completely rule out Influenza B infection.
• If clinical suspicion remains high, molecular testing such as RT-PCR may be recommended.

Rapid influenza tests are useful for quick screening, but they are generally less sensitive than molecular tests. The Influenza B Ag Rapid Test Device should be used as a professional screening aid, and RT-PCR is generally considered more sensitive and specific than rapid antigen testing.

Instructions

• For professional in-vitro diagnostic use only
• Use approved nasal or nasopharyngeal swab specimens only
• Improper specimen collection may affect results
• False-negative results may occur, especially during peak flu activity
• False positive or false negative results may occur
• Negative results may need confirmation if symptoms strongly suggest influenza
• Read results only within the recommended time
• Follow the official product insert carefully

Instructions

• Detects Influenza B antigen
• Uses nasal or nasopharyngeal swab samples
• Rapid visual result
• Simple test procedure
• No complex instrument required
• Suitable for professional point-of-care testing
• Useful during seasonal flu outbreaks
• Supports international diagnostic supply needs

Note

The Influenza B Ag Rapid Test Device by LARKSOIS Pharma is designed for fast, practical, and accessible flu screening.

Steps

• Bring the test device, swab specimen, and extraction buffer to room temperature
• Collect the nasal or nasopharyngeal swab specimen according to instructions
• Place the swab into the extraction buffer tube
• Mix the sample properly as instructed in the product insert
• Remove the test cassette from the sealed pouch
• Apply the prepared specimen to the sample well
• Wait for the recommended reaction time
• Read the test and control lines within the valid time window
• Dispose of used materials according to laboratory safety procedures

Note

Testing should be performed by trained healthcare professionals according to the official LARKSOIS Pharma product insert.

Positive

A positive result means Influenza B antigen has been detected. The result should be interpreted with symptoms, patient history, exposure risk, and local flu activity.

Negative

A negative result means Influenza B antigen was not detected at the test’s detectable level. If clinical suspicion remains high, molecular testing such as RT-PCR may be recommended.

Invalid

If the control line does not appear, the result is invalid. Repeat testing with a new device is required.

Instructions

• Store the Influenza B Ag Rapid Test Device according to the product label and insert
• Store in a cool and dry place
• Keep sealed until use
• Protect from heat, sunlight, and moisture
• Do not freeze unless specified
• Do not use expired kits
• Use immediately after opening the pouch
• Follow all instructions for use carefully

Instructions

• For professional in-vitro diagnostic use only
• Handle respiratory specimens carefully
• Wear gloves and protective equipment during testing
• Do not reuse the test cassette
• Avoid specimen contamination
• Do not use damaged or expired kits
• Read results only within the recommended time
• Interpret results with clinical findings and local flu activity

LARKSOIS Pharma provides internationally suitable diagnostic solutions for hospitals, laboratories, clinics, medical distributors, public health programs, and procurement agencies. The Influenza B Ag Rapid Test Device is designed for fast, practical, and accessible flu screening.

Advantages

• International infectious disease rapid test portfolio
• Reliable Influenza B antigen screening support
• Suitable for hospitals, clinics, and laboratories
• Distributor-friendly product support
• Professional healthcare quality standards
• Practical point-of-care diagnostic format
• Accessible respiratory infection screening solution